PROCEPT BioRobotics Corporation - Common Stock (PRCT)
73.81
+2.22 (3.10%)
Procept Biorobotics Corp is a medical technology company focused on advancing minimally invasive surgical solutions, particularly for the treatment of benign prostate hyperplasia
The company develops innovative robotic-assisted platforms that enhance the precision and effectiveness of procedures, empowering urologists to deliver better patient outcomes while reducing recovery times. Procept aims to transform standard surgical practices through its cutting-edge technology, improving the overall experience for both patients and healthcare providers.
Spruce Point Capital warns of Procept BioRobotics' overstated market potential and growth claims, citing niche product limitations and valuation risks.
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.
SAN JOSE, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 36th Annual Piper Sandler Healthcare Conference in New York City. Management is scheduled to present on Wednesday, December 4 at 8:30 a.m. Eastern Time.
SAN JOSE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQPRCT) (“PROCEPT BioRobotics” or the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the pricing of an underwritten public offering of 1,923,076 shares of its common stock, at a public offering price of $91.00 per share, before underwriting discounts and commissions, for aggregate gross proceeds of approximately $175 million. In addition, a selling stockholder has granted the underwriters a 30-day option to purchase up to an additional 288,461 shares of the Company’s common stock at the public offering price, less underwriting discounts and commissions. PROCEPT BioRobotics will not receive any proceeds from any sale of shares by the selling stockholder. The offering is expected to close on or about October 31, 2024, subject to customary closing conditions.
SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQPRCT) (“PROCEPT BioRobotics” or the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the commencement of an underwritten public offering of $175,000,000 of shares of its common stock. A selling stockholder also expects to grant the underwriters a 30-day option to purchase up to an additional $26,250,000 of shares of the Company’s common stock. PROCEPT BioRobotics will not receive any proceeds from any sale of shares by the selling stockholder. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2024.
SAN JOSE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2024 before market open on Monday, October 28, 2024. The Company’s management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time.
A Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of Aquablation Therapy in Men with Grade Group 1 to 3 Localized Prostate Cancer
SAN JOSE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Wells Fargo Healthcare Conference in Boston, Massachusetts. Management is scheduled to present on Wednesday, September 4 at 1:30 p.m. Eastern Time.
